Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19
Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19 Company expects to begin taking orders from US CLIA labs first week of October 2020 |
[24-September-2020] |
SALT LAKE CITY, Sept. 24, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smartâ„¢ ABC Test (Influenza A/Influenza B/COVID-19) is anticipated to be ready for launch to US CLIA laboratory customers the first week of October 2020. "Co-Diagnostics is committed to participating in the fight against COVID-19 through the development and manufacture of vital diagnostic testing solutions, with none perhaps as important as this upcoming ABC multiplex test," remarked Dwight Egan, CEO of Co-Diagnostics. "Our patented CoPrimerâ„¢ technology platform is ideally suited for multiplex reactions by substantially reducing 'primer-dimers,' a phenomenon in PCR molecular tests that results in false positive results. At a time when the need for accurate detection of COVID-19 as well as the differentiation between strains of the flu has never been greater, we are pleased to be able to contribute to the safety and well-being of communities across the country and around the world." The test will initially be made available to CLIA labs who will be using it in their own laboratory developed tests, or LDTs, while the Company proceeds with the FDA Emergency Use Authorization submission and CE marking registration. About Co-Diagnostics, Inc.: Forward-Looking Statements:
View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-provides-update-on-abc-test-for-influenza-a-influenza-b-and-covid-19-301137243.html SOURCE Co-Diagnostics | ||
Company Codes: NASDAQ-SMALL:CODX |
© 2020 PR Newswire. All Rights Reserved.